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EDITORIAL Open Access
Pharmaceutical policies in a crisis?
Challenges and solutions identified at the
PPRI Conference
Sabine Vogler1*, Nina Zimmermann1, Alessandra Ferrario2, Veronika J. Wirtz3, Kees de Joncheere4,
Hanne Bak Pedersen5, Guillaume Dedet5, Valérie Paris6, Aukje K. Mantel-Teeuwisse7, Zaheer-Ud-Din Babar8
and on behalf of the Scientific Programme Committee of the 2015 PPRI Conference
Abstract
In October 2015, the third international Pharmaceutical Pricing and Reimbursement Information (PPRI) Conference
was held in Vienna to foster discussion on challenges in pricing and reimbursement policies for medicines. The
research presented highlighted that commonly used pharmaceutical pricing and reimbursement policies are not
sufficiently effective to address current challenges. Conference participants called for fundamental reforms to ensure
access to medicines, particularly to new and potentially more effective and/or safe medicines, while safeguarding
the financial sustainability of health systems and working towards universal health coverage.
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Cooperation
The Vienna WHO Collaborating Centre for Pharmaceut-
ical Pricing and Reimbursement held its third inter-
national Pharmaceutical Pricing and Reimbursement
Information (PPRI) Conference in Vienna on 12 and 13
October 2015, coinciding with the tenth anniversary of
PPRI, a network of competent authorities for pharmaceut-
ical pricing and reimbursement from 46 countries [1].
The conference aimed to present the latest pharma-
ceutical policy analyses and to foster discussion on chal-
lenges in pricing and reimbursement policies.
The Conference had a special focus on challenges be-
yond the financial crisis as some countries had been hit
hard by the global financial crisis, and many more have
been struggling to ensure access to medicines for their
population. In addition to funding cuts due to the reces-
sion, public health care systems have been struggling with
the entry of a number of new high-priced medicines in
the past years. The conference addressed this topic
through presentations and debates in plenary as well as in
the three parallel sessions. The latter related to ‘Challenges
and Opportunities for Pricing and Reimbursement Pol-
icies’ [2], ‘Policies beyond the Crisis: Lessons Learned’ [3],
and ‘Policy Cooperation and Interface Issues’ [4].
Around 260 people from 56 countries attended the
conference. Sixty conference delegates contributed to
the event as speakers, panellists or facilitators. High-
level representatives of the World Health Organization
(WHO), competent authorities and associations as well
as outstanding researchers gave key-note speeches and
made interventions during debates. Abstracts submitted
by researchers had been evaluated and ranked by the Sci-
entific Programme Committee. Authors of high-ranking
abstracts were invited for oral or poster presentation. Kim
Pauwels (KU Leuven, Belgium) received the Young Re-
searcher Award; Susanne Spillane (National Centre for
Pharmacoeconomics, Ireland) and Jaana Martikainen (So-
cial Insurance Institution, Finland) were awarded for the
best oral presentation and the best poster, respectively.
High-priced medicines
From the very beginning of the PPRI Conference, which
started with the key-note speech of Suzanne Hill, Senior
Adviser at the Essential Medicines and Health Products
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Department of WHO and a stakeholder roundtable (rep-
resentatives from the payers, regulatory authorities, in-
dustry and consumers), conference participants pointed
to the urgent need for pharmaceutical policy reforms.
While reforms would need to respond to the impact of
financial austerity, more importantly, they should ad-
dress existing inefficiencies in health and pharmaceutical
systems. The need for reform is becoming all the more
urgent due to affordability and opportunity costs issues.
These are driven by several factors including the very
high prices of some new medicines - such as treatments
for hepatitis C, cancer and rare conditions - the upcom-
ing marketing of high-priced medicines currently under
development, demographic and epidemiological changes,
and the wide disparities in available resources across and
within countries. It was acknowledged that a reimburse-
ment decision related to one single medicine could im-
pose a high financial burden for the whole health care
system and could eventually limit or crowd out other ef-
fective medicines, technologies or health ressources.
Medicines with high budget impact have also chal-
lenged the role of economic evaluations, as Florent
Dromzée of the French Ministry of Health explained in
his case study on sofosbuvir. The assessment of sofosbu-
vir highlighted the limitations of the cost-effectiveness
analysis and the importance of distinguishing efficiency
and affordability. Five new direct acting oral antiretro-
viral medicines have recently come on the market trans-
forming the treatment of chronic hepatitis C, and
sixteen new oncology medicines were added to the
WHO Essential Medicines List (EML) during the 2015
review [5]. These are very effective medicines but un-
affordable for many countries, as explained Nicola
Magrini, Essential Medicines List Secretary at WHO. In-
cluding such medicines in the list is seen as a first step
towards increasing access for patients together with
comprehensive essential medicines policies [6]. Their
listing on the WHO EML is envisaged to send a strong
message that these medicines need to become affordable.
Some tools to achieve this are already available – differ-
ential pricing, generic competition, and joint and/or
strategic procurement–, but their implementation re-
mains often limited and/or not targeted to where need is
greatest.
Barriers to access
Limited access to medicines is no longer solely an issue
for low- and middle-income countries. In the stakeholder
roundtable, Tim Reed of Health Action International
quoted a World Health Assembly delegate commenting
on the challenges of affordability and availability of medi-
cines at the global level by extending a ‘Welcome to our
world of scarcity!’ to high-income countries. Several con-
ference abstracts identified variations and limitations not
only related to affordability but also in the availability of
medicines in different countries and regions [7–9].
In addition to limited accessibility of high-priced med-
icines, an increasing number of countries, particularly
low- and middle-income countries, face problems of
availability of some ‘old’ off-patent medicines with low
prices, that are no longer produced and marketed, as Su-
zanne Hill stressed in her key-note talk. These products
are essential medicines that had been marketed for a long
time but whose prices appear to not be viable or not inter-
esting enough for industry to continue production.
Limitations of external price referencing
While conference participants were aware of the mul-
tiple causes of availability problems related to medicines,
it was acknowledged that current pricing policies are
likely to be an important contributor to this problem.
This is in particular true for the policy of external price
referencing (EPR), i.e. the practice of using the price(s)
of a medicine in one or several countries in order to de-
rive a benchmark or reference price for the purposes of
setting or negotiating the price of the product in a given
country [10]. Use of external price referencing incenti-
vises manufacturers to first launch a medicine in coun-
tries with high prices and to delay market entry or not
launch at all in lower-income countries in order not to
reduce the benchmark reference price. This issue was
addressed in several discussions at the PPRI Conference.
The limitation of using list prices when conducting
EPR instead of actual discounted prices was also
highlighted during the Conference. Payers are aware that
with this policy they are likely to over-pay. Threats by
industry that price transparency will prevent them from
continuing to offer discounts to individual countries
does not incentivise many countries to share data al-
though the case of hepatitis C seems to have started trig-
gering a change in attitude. Several conference delegates,
in particular consumers and patients, called for more
transparency about which elements go into the final
medicine prices, and for a disclosure of discounts. Peter
Schneider of the Austrian Public Health Institute illus-
trated, in an exploratory case study, how the results of a
European price comparison would change, when the
published discounted prices in Germany were used in-
stead of list prices (9).
In many European countries external price referencing
remains a key pricing policy for new medicines, as the
country presentations and posters demonstrated [11].
Are managed-entry agreements the answer?
A survey among competent authorities in Europe,
undertaken in the framework of a technical review of
WHO Europe on access to new medicines [12], con-
firmed, in principle, the use of ‘traditional’ policies for
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new medicines. However, pharmaco-economic evalua-
tions and health technology assessments (HTA) as well
as managed-entry agreements (MEAs) play an increasing
role for new high-priced medicines [13].
Suggestions were made on how to make better use of
HTA and pharmaco-economic evaluations in the
decision-making process: Aris Angelis (London School
of Economics, UK) proposed the application of multi-
decision criteria analysis methods in reimbursement
decisions [14, 15]. Based on the example of national as-
sessments for sofosbuvir analysed in the framework of
the EUNetHTA project, Wim Goettsch (National Health
Care Institute, the Netherlands) urged for improved co-
operation on HTA in Europe. Seven months after sofos-
buvir received market authorisation, the assessment of
the effectiveness had not yet started in 11 countries
(thereof five European countries where no application
for reimbursement had been submitted), it was ongoing
in nine and it was completed in eight. Wim Goettsch con-
cluded that marketing authorization holders appeared to
set the pace of HTA assessments. This reduced the possi-
bilities for payers to participate in voluntary joint price ne-
gotiations [16].
Managed-entry agreements were proposed as a pos-
sible solution, at least short-term, to grant access to new
medicines that seemed to be providing therapeutic bene-
fits for patients. But their limitations were clearly ad-
dressed by several conference participants. For example,
Suzanne Hill from WHO reminded payers that opting
for MEAs may mean implicitly accepting high (list) prices.
In her presentation on high-cost cancer medicines in
Australia, Agnes Vitry (University of South Australia)
called for more transparency related to confidential MEAs
[17]. In the stakeholder roundtable, Richard Bergström of
the European Federation of Pharmaceutical Industries and
Associations (EFPIA) expressed the industry’s preference
for MEAs. He is convinced that confidential discounts,
such as those connected to MEAs, would remain in fu-
ture. However, he challenged payers for not yielding better
negotiation results: ‘Despite being monopsonists, you are
not good purchasers.’ The different perspectives with re-
gard to MEAs were also described in a qualitative research
performed by Kim Pauwels (KU Leuven, Belgium). Her
study showed the advantages and disadvantages of MEAs
as perceived by different stakeholders in Belgium and sug-
gested a lack of trust of payers in pharmaceutical compan-
ies and vice versa [18].
Be prepared!
The watchword of the PPRI conference was: ‘Be pre-
pared!’ Conference delegates stressed the relevance of
horizon scanning exercises, i.e. identification and early
assessments of new and emerging technologies in health-
care to support decision-making, and of the authorities’
cooperation with pharmaceutical industry to obtain infor-
mation on new medicines under development. There was
agreement that horizon scanning is not an easy task since
this requires a body of data that might not be easily ac-
cessible. Industry noted that, for the time being, it appears
to be misaligned with other activities undertaken by
policy-makers. Anna Nachtnebel (Ludwig Boltzmann
Institute for Health Technology Assessment, Austria) re-
ported on the strengths and weaknesses of early awareness
and alert systems in the area of oncology medicines to in-
form authorities about medicines technologies that may
have a significant impact on the health care system [19].
Generic and biosimilar competition
Although a major part of the discussion was focused on
new, high-priced medicines, generics and biosimilar
medicines were also addressed as a possible part of the
solution in managing pharmaceutical expenditure and
improving access to medicines in European countries
and globally. While generics are expected to drive medi-
cine prices down, it was stressed how important the de-
sign of policy measures is in order to reap the benefits
of generics competition. Examples from Belgium and
Finland were presented where the reference price sys-
tems (internal price referencing based on generics) did
not prove to be as successful as expected due to their
policy design [20, 21].
In his key-note speech, Arnold Vulto (Erasmus Uni-
versity Medical Center Rotterdam, the Netherlands)
showed the potential of biosimilar medicines in lowering
prices, but he had some warnings: the uptake of biosimi-
lar medicines might be slower than that of generics and
will rely on the creation of trust and confidence among
all the stakeholders involved such as prescribers, phar-
macists, patients. In addition, while the cost per treat-
ment day would likely go down, the overall public
expenditure could grow due to increased access.
Conclusions
The PPRI Conference concluded that, in order to ad-
dress the outlined challenges, it is important to use a
mix of policies to address the numerous and complex is-
sues affecting access to on-patent and off-patent medi-
cines. In line with the WHO Review on Access to New
Medicines in Europe [12] it was suggested that - in
addition to common and new approaches in pricing and
reimbursement (peri-launch activities) - policy-makers
should consider applying the full spectrum of policy op-
tions, including pre-launch activities that provide a
forward-looking perspective on new medicines in devel-
opment and post-launch activities that address respon-
sible and sustainable use of medicines.
Moreover, a broader review beyond pricing and reim-
bursement policies is needed that includes the current
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patent system and considers new models that aim to de-
link a medicine price from the return on investment into
research and development [22, 23]. Several conference
presenters and participants called for more transparency
related to the costs of R&D.
Any discussion on new strategies requires dialogue
with all relevant stakeholders. The role of patients and
citizens was stressed during the PPRI conference whose
closing commentary entitled ‘Patients have the last
word?’ was given by Nicola Bedlington of the European
Patients Forum. She explained that patients can under-
stand and are willing to accept priority setting by policy-
makers if the decisions were appropriately justified and
communicated.
The PPRI Conference identified areas of particular
relevance for collaborative approaches among policy-
makers and stakeholders. Cooperation related to HTA
and horizon scanning should continue and be extended.
Furthermore, participants recommended joining forces
on strategic procurement and on measures beyond pri-
cing policies.
Further information
All materials of the conference (presentations, abstract
poster book, country poster book) are freely available for
download at the PPRI Conference website: http://whocc.
goeg.at/Conference2015/Programme.
The accepted abstracts were, together with editorials
and commentaries, published in the PPRI Conference
Supplement: http://www.joppp.org/supplements/8/S1/all.
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